Pharma & Healthcare
Global Oral Medications for Multiple Sclerosis Market Research Report 2024
- Sep 18, 24
- ID: 553598
- Pages: 113
- Figures: 114
- Views: 1
Oral medications for Multiple Sclerosis (MS) are drugs that work by targeting the immune system to reduce inflammation, prevent relapses, or slow the progression of the disease,including dimethyl fumarate, teriflunomide, fingolimod, Ozanimod and so on.
The global Oral Medications for Multiple Sclerosis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oral Medications for Multiple Sclerosis include Janssen, Novartis, Sanofi, Biogen, Banner Life Sciences, Bristol Myers Squibb, Merck, Qilu Pharmaceutical, Sichuan Omnis Pharmaceutical, HEC Pharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oral Medications for Multiple Sclerosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Medications for Multiple Sclerosis.
The Oral Medications for Multiple Sclerosis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Oral Medications for Multiple Sclerosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Medications for Multiple Sclerosis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Janssen
Novartis
Sanofi
Biogen
Banner Life Sciences
Bristol Myers Squibb
Merck
Qilu Pharmaceutical
Sichuan Omnis Pharmaceutical
HEC Pharm
Cisen Pharmaceutical
Nanjing Healthnice Pharmaceutical
CGeneTech (Suzhou, China)
Mylan
Zydus
Accord Healthcare
Dr. Reddy's Laboratories
Glenmark Pharmaceuticals
Teva
Sandoz
Viatris
Sun Pharmaceuticals
Alembic
Apotex
Segment by Type
Dimethyl Fumarate
Fingolimod
Teriflunomide
Diroximel Fumarate
Monomethyl Fumarate
Siponimod
Ozanimod
Ponesimod
Cladribine
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Medications for Multiple Sclerosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Medications for Multiple Sclerosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Oral Medications for Multiple Sclerosis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oral Medications for Multiple Sclerosis include Janssen, Novartis, Sanofi, Biogen, Banner Life Sciences, Bristol Myers Squibb, Merck, Qilu Pharmaceutical, Sichuan Omnis Pharmaceutical, HEC Pharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oral Medications for Multiple Sclerosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Medications for Multiple Sclerosis.
The Oral Medications for Multiple Sclerosis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Oral Medications for Multiple Sclerosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Medications for Multiple Sclerosis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Janssen
Novartis
Sanofi
Biogen
Banner Life Sciences
Bristol Myers Squibb
Merck
Qilu Pharmaceutical
Sichuan Omnis Pharmaceutical
HEC Pharm
Cisen Pharmaceutical
Nanjing Healthnice Pharmaceutical
CGeneTech (Suzhou, China)
Mylan
Zydus
Accord Healthcare
Dr. Reddy's Laboratories
Glenmark Pharmaceuticals
Teva
Sandoz
Viatris
Sun Pharmaceuticals
Alembic
Apotex
Segment by Type
Dimethyl Fumarate
Fingolimod
Teriflunomide
Diroximel Fumarate
Monomethyl Fumarate
Siponimod
Ozanimod
Ponesimod
Cladribine
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Medications for Multiple Sclerosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Medications for Multiple Sclerosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Oral Medications for Multiple Sclerosis Market Overview
1.1 Product Definition
1.2 Oral Medications for Multiple Sclerosis by Type
1.2.1 Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2024-2030)
1.2.2 Dimethyl Fumarate
1.2.3 Fingolimod
1.2.4 Teriflunomide
1.2.5 Diroximel Fumarate
1.2.6 Monomethyl Fumarate
1.2.7 Siponimod
1.2.8 Ozanimod
1.2.9 Ponesimod
1.2.10 Cladribine
1.3 Oral Medications for Multiple Sclerosis by Application
1.3.1 Global Oral Medications for Multiple Sclerosis Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Oral Medications for Multiple Sclerosis Market Size Estimates and Forecasts
1.4.1 Global Oral Medications for Multiple Sclerosis Revenue 2019-2030
1.4.2 Global Oral Medications for Multiple Sclerosis Sales 2019-2030
1.4.3 Global Oral Medications for Multiple Sclerosis Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral Medications for Multiple Sclerosis Market Competition by Manufacturers
2.1 Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oral Medications for Multiple Sclerosis Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Oral Medications for Multiple Sclerosis, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Product Type & Application
2.7 Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Date of Enter into This Industry
2.8 Global Oral Medications for Multiple Sclerosis Market Competitive Situation and Trends
2.8.1 Global Oral Medications for Multiple Sclerosis Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oral Medications for Multiple Sclerosis Players Market Share by Revenue
2.8.3 Global Oral Medications for Multiple Sclerosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oral Medications for Multiple Sclerosis Market Scenario by Region
3.1 Global Oral Medications for Multiple Sclerosis Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral Medications for Multiple Sclerosis Sales by Region: 2019-2030
3.2.1 Global Oral Medications for Multiple Sclerosis Sales by Region: 2019-2024
3.2.2 Global Oral Medications for Multiple Sclerosis Sales by Region: 2025-2030
3.3 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2019-2030
3.3.1 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2019-2024
3.3.2 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2025-2030
3.4 North America Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.4.1 North America Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.4.3 North America Oral Medications for Multiple Sclerosis Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.5.1 Europe Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.5.3 Europe Oral Medications for Multiple Sclerosis Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Medications for Multiple Sclerosis Market Facts & Figures by Region
3.6.1 Asia Pacific Oral Medications for Multiple Sclerosis Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2019-2030)
3.6.3 Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.7.1 Latin America Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.7.3 Latin America Oral Medications for Multiple Sclerosis Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2019-2030)
4.1.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2019-2024)
4.1.2 Global Oral Medications for Multiple Sclerosis Sales by Type (2025-2030)
4.1.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2019-2030)
4.2 Global Oral Medications for Multiple Sclerosis Revenue by Type (2019-2030)
4.2.1 Global Oral Medications for Multiple Sclerosis Revenue by Type (2019-2024)
4.2.2 Global Oral Medications for Multiple Sclerosis Revenue by Type (2025-2030)
4.2.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2019-2030)
4.3 Global Oral Medications for Multiple Sclerosis Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2019-2030)
5.1.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2019-2024)
5.1.2 Global Oral Medications for Multiple Sclerosis Sales by Application (2025-2030)
5.1.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2019-2030)
5.2 Global Oral Medications for Multiple Sclerosis Revenue by Application (2019-2030)
5.2.1 Global Oral Medications for Multiple Sclerosis Revenue by Application (2019-2024)
5.2.2 Global Oral Medications for Multiple Sclerosis Revenue by Application (2025-2030)
5.2.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2019-2030)
5.3 Global Oral Medications for Multiple Sclerosis Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Janssen
6.1.1 Janssen Company Information
6.1.2 Janssen Description and Business Overview
6.1.3 Janssen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Janssen Oral Medications for Multiple Sclerosis Product Portfolio
6.1.5 Janssen Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Oral Medications for Multiple Sclerosis Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Oral Medications for Multiple Sclerosis Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Biogen
6.4.1 Biogen Company Information
6.4.2 Biogen Description and Business Overview
6.4.3 Biogen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Oral Medications for Multiple Sclerosis Product Portfolio
6.4.5 Biogen Recent Developments/Updates
6.5 Banner Life Sciences
6.5.1 Banner Life Sciences Company Information
6.5.2 Banner Life Sciences Description and Business Overview
6.5.3 Banner Life Sciences Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio
6.5.5 Banner Life Sciences Recent Developments/Updates
6.6 Bristol Myers Squibb
6.6.1 Bristol Myers Squibb Company Information
6.6.2 Bristol Myers Squibb Description and Business Overview
6.6.3 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio
6.6.5 Bristol Myers Squibb Recent Developments/Updates
6.7 Merck
6.7.1 Merck Company Information
6.7.2 Merck Description and Business Overview
6.7.3 Merck Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Merck Oral Medications for Multiple Sclerosis Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Qilu Pharmaceutical
6.8.1 Qilu Pharmaceutical Company Information
6.8.2 Qilu Pharmaceutical Description and Business Overview
6.8.3 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.8.5 Qilu Pharmaceutical Recent Developments/Updates
6.9 Sichuan Omnis Pharmaceutical
6.9.1 Sichuan Omnis Pharmaceutical Company Information
6.9.2 Sichuan Omnis Pharmaceutical Description and Business Overview
6.9.3 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.9.5 Sichuan Omnis Pharmaceutical Recent Developments/Updates
6.10 HEC Pharm
6.10.1 HEC Pharm Company Information
6.10.2 HEC Pharm Description and Business Overview
6.10.3 HEC Pharm Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.10.4 HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio
6.10.5 HEC Pharm Recent Developments/Updates
6.11 Cisen Pharmaceutical
6.11.1 Cisen Pharmaceutical Company Information
6.11.2 Cisen Pharmaceutical Description and Business Overview
6.11.3 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.11.5 Cisen Pharmaceutical Recent Developments/Updates
6.12 Nanjing Healthnice Pharmaceutical
6.12.1 Nanjing Healthnice Pharmaceutical Company Information
6.12.2 Nanjing Healthnice Pharmaceutical Description and Business Overview
6.12.3 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.12.5 Nanjing Healthnice Pharmaceutical Recent Developments/Updates
6.13 CGeneTech (Suzhou, China)
6.13.1 CGeneTech (Suzhou, China) Company Information
6.13.2 CGeneTech (Suzhou, China) Description and Business Overview
6.13.3 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio
6.13.5 CGeneTech (Suzhou, China) Recent Developments/Updates
6.14 Mylan
6.14.1 Mylan Company Information
6.14.2 Mylan Description and Business Overview
6.14.3 Mylan Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Mylan Oral Medications for Multiple Sclerosis Product Portfolio
6.14.5 Mylan Recent Developments/Updates
6.15 Zydus
6.15.1 Zydus Company Information
6.15.2 Zydus Description and Business Overview
6.15.3 Zydus Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Zydus Oral Medications for Multiple Sclerosis Product Portfolio
6.15.5 Zydus Recent Developments/Updates
6.16 Accord Healthcare
6.16.1 Accord Healthcare Company Information
6.16.2 Accord Healthcare Description and Business Overview
6.16.3 Accord Healthcare Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio
6.16.5 Accord Healthcare Recent Developments/Updates
6.17 Dr. Reddy's Laboratories
6.17.1 Dr. Reddy's Laboratories Company Information
6.17.2 Dr. Reddy's Laboratories Description and Business Overview
6.17.3 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio
6.17.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.18 Glenmark Pharmaceuticals
6.18.1 Glenmark Pharmaceuticals Company Information
6.18.2 Glenmark Pharmaceuticals Description and Business Overview
6.18.3 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
6.18.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.19 Teva
6.19.1 Teva Company Information
6.19.2 Teva Description and Business Overview
6.19.3 Teva Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Teva Oral Medications for Multiple Sclerosis Product Portfolio
6.19.5 Teva Recent Developments/Updates
6.20 Sandoz
6.20.1 Sandoz Company Information
6.20.2 Sandoz Description and Business Overview
6.20.3 Sandoz Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Sandoz Oral Medications for Multiple Sclerosis Product Portfolio
6.20.5 Sandoz Recent Developments/Updates
6.21 Viatris
6.21.1 Viatris Company Information
6.21.2 Viatris Description and Business Overview
6.21.3 Viatris Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Viatris Oral Medications for Multiple Sclerosis Product Portfolio
6.21.5 Viatris Recent Developments/Updates
6.22 Sun Pharmaceuticals
6.22.1 Sun Pharmaceuticals Company Information
6.22.2 Sun Pharmaceuticals Description and Business Overview
6.22.3 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
6.22.5 Sun Pharmaceuticals Recent Developments/Updates
6.23 Alembic
6.23.1 Alembic Company Information
6.23.2 Alembic Description and Business Overview
6.23.3 Alembic Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Alembic Oral Medications for Multiple Sclerosis Product Portfolio
6.23.5 Alembic Recent Developments/Updates
6.24 Apotex
6.24.1 Apotex Company Information
6.24.2 Apotex Description and Business Overview
6.24.3 Apotex Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Apotex Oral Medications for Multiple Sclerosis Product Portfolio
6.24.5 Apotex Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Medications for Multiple Sclerosis Industry Chain Analysis
7.2 Oral Medications for Multiple Sclerosis Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Medications for Multiple Sclerosis Production Mode & Process
7.4 Oral Medications for Multiple Sclerosis Sales and Marketing
7.4.1 Oral Medications for Multiple Sclerosis Sales Channels
7.4.2 Oral Medications for Multiple Sclerosis Distributors
7.5 Oral Medications for Multiple Sclerosis Customers
8 Oral Medications for Multiple Sclerosis Market Dynamics
8.1 Oral Medications for Multiple Sclerosis Industry Trends
8.2 Oral Medications for Multiple Sclerosis Market Drivers
8.3 Oral Medications for Multiple Sclerosis Market Challenges
8.4 Oral Medications for Multiple Sclerosis Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Oral Medications for Multiple Sclerosis by Type
1.2.1 Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2024-2030)
1.2.2 Dimethyl Fumarate
1.2.3 Fingolimod
1.2.4 Teriflunomide
1.2.5 Diroximel Fumarate
1.2.6 Monomethyl Fumarate
1.2.7 Siponimod
1.2.8 Ozanimod
1.2.9 Ponesimod
1.2.10 Cladribine
1.3 Oral Medications for Multiple Sclerosis by Application
1.3.1 Global Oral Medications for Multiple Sclerosis Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Oral Medications for Multiple Sclerosis Market Size Estimates and Forecasts
1.4.1 Global Oral Medications for Multiple Sclerosis Revenue 2019-2030
1.4.2 Global Oral Medications for Multiple Sclerosis Sales 2019-2030
1.4.3 Global Oral Medications for Multiple Sclerosis Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral Medications for Multiple Sclerosis Market Competition by Manufacturers
2.1 Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oral Medications for Multiple Sclerosis Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Oral Medications for Multiple Sclerosis, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Product Type & Application
2.7 Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Date of Enter into This Industry
2.8 Global Oral Medications for Multiple Sclerosis Market Competitive Situation and Trends
2.8.1 Global Oral Medications for Multiple Sclerosis Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oral Medications for Multiple Sclerosis Players Market Share by Revenue
2.8.3 Global Oral Medications for Multiple Sclerosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oral Medications for Multiple Sclerosis Market Scenario by Region
3.1 Global Oral Medications for Multiple Sclerosis Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral Medications for Multiple Sclerosis Sales by Region: 2019-2030
3.2.1 Global Oral Medications for Multiple Sclerosis Sales by Region: 2019-2024
3.2.2 Global Oral Medications for Multiple Sclerosis Sales by Region: 2025-2030
3.3 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2019-2030
3.3.1 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2019-2024
3.3.2 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2025-2030
3.4 North America Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.4.1 North America Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.4.3 North America Oral Medications for Multiple Sclerosis Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.5.1 Europe Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.5.3 Europe Oral Medications for Multiple Sclerosis Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Medications for Multiple Sclerosis Market Facts & Figures by Region
3.6.1 Asia Pacific Oral Medications for Multiple Sclerosis Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2019-2030)
3.6.3 Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.7.1 Latin America Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.7.3 Latin America Oral Medications for Multiple Sclerosis Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oral Medications for Multiple Sclerosis Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2019-2030)
4.1.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2019-2024)
4.1.2 Global Oral Medications for Multiple Sclerosis Sales by Type (2025-2030)
4.1.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2019-2030)
4.2 Global Oral Medications for Multiple Sclerosis Revenue by Type (2019-2030)
4.2.1 Global Oral Medications for Multiple Sclerosis Revenue by Type (2019-2024)
4.2.2 Global Oral Medications for Multiple Sclerosis Revenue by Type (2025-2030)
4.2.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2019-2030)
4.3 Global Oral Medications for Multiple Sclerosis Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2019-2030)
5.1.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2019-2024)
5.1.2 Global Oral Medications for Multiple Sclerosis Sales by Application (2025-2030)
5.1.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2019-2030)
5.2 Global Oral Medications for Multiple Sclerosis Revenue by Application (2019-2030)
5.2.1 Global Oral Medications for Multiple Sclerosis Revenue by Application (2019-2024)
5.2.2 Global Oral Medications for Multiple Sclerosis Revenue by Application (2025-2030)
5.2.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2019-2030)
5.3 Global Oral Medications for Multiple Sclerosis Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Janssen
6.1.1 Janssen Company Information
6.1.2 Janssen Description and Business Overview
6.1.3 Janssen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Janssen Oral Medications for Multiple Sclerosis Product Portfolio
6.1.5 Janssen Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Oral Medications for Multiple Sclerosis Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Oral Medications for Multiple Sclerosis Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Biogen
6.4.1 Biogen Company Information
6.4.2 Biogen Description and Business Overview
6.4.3 Biogen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Oral Medications for Multiple Sclerosis Product Portfolio
6.4.5 Biogen Recent Developments/Updates
6.5 Banner Life Sciences
6.5.1 Banner Life Sciences Company Information
6.5.2 Banner Life Sciences Description and Business Overview
6.5.3 Banner Life Sciences Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio
6.5.5 Banner Life Sciences Recent Developments/Updates
6.6 Bristol Myers Squibb
6.6.1 Bristol Myers Squibb Company Information
6.6.2 Bristol Myers Squibb Description and Business Overview
6.6.3 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio
6.6.5 Bristol Myers Squibb Recent Developments/Updates
6.7 Merck
6.7.1 Merck Company Information
6.7.2 Merck Description and Business Overview
6.7.3 Merck Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Merck Oral Medications for Multiple Sclerosis Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Qilu Pharmaceutical
6.8.1 Qilu Pharmaceutical Company Information
6.8.2 Qilu Pharmaceutical Description and Business Overview
6.8.3 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.8.5 Qilu Pharmaceutical Recent Developments/Updates
6.9 Sichuan Omnis Pharmaceutical
6.9.1 Sichuan Omnis Pharmaceutical Company Information
6.9.2 Sichuan Omnis Pharmaceutical Description and Business Overview
6.9.3 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.9.5 Sichuan Omnis Pharmaceutical Recent Developments/Updates
6.10 HEC Pharm
6.10.1 HEC Pharm Company Information
6.10.2 HEC Pharm Description and Business Overview
6.10.3 HEC Pharm Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.10.4 HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio
6.10.5 HEC Pharm Recent Developments/Updates
6.11 Cisen Pharmaceutical
6.11.1 Cisen Pharmaceutical Company Information
6.11.2 Cisen Pharmaceutical Description and Business Overview
6.11.3 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.11.5 Cisen Pharmaceutical Recent Developments/Updates
6.12 Nanjing Healthnice Pharmaceutical
6.12.1 Nanjing Healthnice Pharmaceutical Company Information
6.12.2 Nanjing Healthnice Pharmaceutical Description and Business Overview
6.12.3 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
6.12.5 Nanjing Healthnice Pharmaceutical Recent Developments/Updates
6.13 CGeneTech (Suzhou, China)
6.13.1 CGeneTech (Suzhou, China) Company Information
6.13.2 CGeneTech (Suzhou, China) Description and Business Overview
6.13.3 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio
6.13.5 CGeneTech (Suzhou, China) Recent Developments/Updates
6.14 Mylan
6.14.1 Mylan Company Information
6.14.2 Mylan Description and Business Overview
6.14.3 Mylan Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Mylan Oral Medications for Multiple Sclerosis Product Portfolio
6.14.5 Mylan Recent Developments/Updates
6.15 Zydus
6.15.1 Zydus Company Information
6.15.2 Zydus Description and Business Overview
6.15.3 Zydus Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Zydus Oral Medications for Multiple Sclerosis Product Portfolio
6.15.5 Zydus Recent Developments/Updates
6.16 Accord Healthcare
6.16.1 Accord Healthcare Company Information
6.16.2 Accord Healthcare Description and Business Overview
6.16.3 Accord Healthcare Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio
6.16.5 Accord Healthcare Recent Developments/Updates
6.17 Dr. Reddy's Laboratories
6.17.1 Dr. Reddy's Laboratories Company Information
6.17.2 Dr. Reddy's Laboratories Description and Business Overview
6.17.3 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio
6.17.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.18 Glenmark Pharmaceuticals
6.18.1 Glenmark Pharmaceuticals Company Information
6.18.2 Glenmark Pharmaceuticals Description and Business Overview
6.18.3 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
6.18.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.19 Teva
6.19.1 Teva Company Information
6.19.2 Teva Description and Business Overview
6.19.3 Teva Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Teva Oral Medications for Multiple Sclerosis Product Portfolio
6.19.5 Teva Recent Developments/Updates
6.20 Sandoz
6.20.1 Sandoz Company Information
6.20.2 Sandoz Description and Business Overview
6.20.3 Sandoz Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Sandoz Oral Medications for Multiple Sclerosis Product Portfolio
6.20.5 Sandoz Recent Developments/Updates
6.21 Viatris
6.21.1 Viatris Company Information
6.21.2 Viatris Description and Business Overview
6.21.3 Viatris Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Viatris Oral Medications for Multiple Sclerosis Product Portfolio
6.21.5 Viatris Recent Developments/Updates
6.22 Sun Pharmaceuticals
6.22.1 Sun Pharmaceuticals Company Information
6.22.2 Sun Pharmaceuticals Description and Business Overview
6.22.3 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
6.22.5 Sun Pharmaceuticals Recent Developments/Updates
6.23 Alembic
6.23.1 Alembic Company Information
6.23.2 Alembic Description and Business Overview
6.23.3 Alembic Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Alembic Oral Medications for Multiple Sclerosis Product Portfolio
6.23.5 Alembic Recent Developments/Updates
6.24 Apotex
6.24.1 Apotex Company Information
6.24.2 Apotex Description and Business Overview
6.24.3 Apotex Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Apotex Oral Medications for Multiple Sclerosis Product Portfolio
6.24.5 Apotex Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Medications for Multiple Sclerosis Industry Chain Analysis
7.2 Oral Medications for Multiple Sclerosis Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Medications for Multiple Sclerosis Production Mode & Process
7.4 Oral Medications for Multiple Sclerosis Sales and Marketing
7.4.1 Oral Medications for Multiple Sclerosis Sales Channels
7.4.2 Oral Medications for Multiple Sclerosis Distributors
7.5 Oral Medications for Multiple Sclerosis Customers
8 Oral Medications for Multiple Sclerosis Market Dynamics
8.1 Oral Medications for Multiple Sclerosis Industry Trends
8.2 Oral Medications for Multiple Sclerosis Market Drivers
8.3 Oral Medications for Multiple Sclerosis Market Challenges
8.4 Oral Medications for Multiple Sclerosis Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Oral Medications for Multiple Sclerosis Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Oral Medications for Multiple Sclerosis Market Competitive Situation by Manufacturers in 2023
Table 4. Global Oral Medications for Multiple Sclerosis Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Oral Medications for Multiple Sclerosis Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Oral Medications for Multiple Sclerosis, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Product Type & Application
Table 12. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Medications for Multiple Sclerosis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Medications for Multiple Sclerosis as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Oral Medications for Multiple Sclerosis Sales by Region (2019-2024) & (K Units)
Table 18. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2019-2024)
Table 19. Global Oral Medications for Multiple Sclerosis Sales by Region (2025-2030) & (K Units)
Table 20. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2025-2030)
Table 21. Global Oral Medications for Multiple Sclerosis Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2019-2024)
Table 23. Global Oral Medications for Multiple Sclerosis Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2025-2030)
Table 25. North America Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 27. North America Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 28. North America Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Oral Medications for Multiple Sclerosis Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 32. Europe Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 33. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 47. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 48. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Type (2019-2024)
Table 51. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Type (2025-2030)
Table 52. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2019-2024)
Table 53. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2025-2030)
Table 54. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2019-2024)
Table 57. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2025-2030)
Table 58. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2019-2024)
Table 59. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2025-2030)
Table 60. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Application (2019-2024)
Table 61. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Application (2025-2030)
Table 62. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2019-2024)
Table 63. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2025-2030)
Table 64. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2019-2024)
Table 67. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2025-2030)
Table 68. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2019-2024)
Table 69. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2025-2030)
Table 70. Janssen Company Information
Table 71. Janssen Description and Business Overview
Table 72. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Janssen Oral Medications for Multiple Sclerosis Product
Table 74. Janssen Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Novartis Oral Medications for Multiple Sclerosis Product
Table 79. Novartis Recent Developments/Updates
Table 80. Sanofi Company Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Sanofi Oral Medications for Multiple Sclerosis Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Biogen Company Information
Table 86. Biogen Description and Business Overview
Table 87. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Biogen Oral Medications for Multiple Sclerosis Product
Table 89. Biogen Recent Developments/Updates
Table 90. Banner Life Sciences Company Information
Table 91. Banner Life Sciences Description and Business Overview
Table 92. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Banner Life Sciences Oral Medications for Multiple Sclerosis Product
Table 94. Banner Life Sciences Recent Developments/Updates
Table 95. Bristol Myers Squibb Company Information
Table 96. Bristol Myers Squibb Description and Business Overview
Table 97. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product
Table 99. Bristol Myers Squibb Recent Developments/Updates
Table 100. Merck Company Information
Table 101. Merck Description and Business Overview
Table 102. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Merck Oral Medications for Multiple Sclerosis Product
Table 104. Merck Recent Developments/Updates
Table 105. Qilu Pharmaceutical Company Information
Table 106. Qilu Pharmaceutical Description and Business Overview
Table 107. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 109. Qilu Pharmaceutical Recent Developments/Updates
Table 110. Sichuan Omnis Pharmaceutical Company Information
Table 111. Sichuan Omnis Pharmaceutical Description and Business Overview
Table 112. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 114. Sichuan Omnis Pharmaceutical Recent Developments/Updates
Table 115. HEC Pharm Company Information
Table 116. HEC Pharm Description and Business Overview
Table 117. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. HEC Pharm Oral Medications for Multiple Sclerosis Product
Table 119. HEC Pharm Recent Developments/Updates
Table 120. Cisen Pharmaceutical Company Information
Table 121. Cisen Pharmaceutical Description and Business Overview
Table 122. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 124. Cisen Pharmaceutical Recent Developments/Updates
Table 125. Nanjing Healthnice Pharmaceutical Company Information
Table 126. Nanjing Healthnice Pharmaceutical Description and Business Overview
Table 127. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 129. Nanjing Healthnice Pharmaceutical Recent Developments/Updates
Table 130. CGeneTech (Suzhou, China) Company Information
Table 131. CGeneTech (Suzhou, China) Description and Business Overview
Table 132. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product
Table 134. CGeneTech (Suzhou, China) Recent Developments/Updates
Table 135. Mylan Company Information
Table 136. Mylan Description and Business Overview
Table 137. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Mylan Oral Medications for Multiple Sclerosis Product
Table 139. Mylan Recent Developments/Updates
Table 140. Zydus Company Information
Table 141. Zydus Description and Business Overview
Table 142. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Zydus Oral Medications for Multiple Sclerosis Product
Table 144. Zydus Recent Developments/Updates
Table 145. Accord Healthcare Company Information
Table 146. Accord Healthcare Description and Business Overview
Table 147. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Accord Healthcare Oral Medications for Multiple Sclerosis Product
Table 149. Accord Healthcare Recent Developments/Updates
Table 150. Dr. Reddy's Laboratories Company Information
Table 151. Dr. Reddy's Laboratories Description and Business Overview
Table 152. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product
Table 154. Dr. Reddy's Laboratories Recent Developments/Updates
Table 155. Glenmark Pharmaceuticals Company Information
Table 156. Glenmark Pharmaceuticals Description and Business Overview
Table 157. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product
Table 159. Glenmark Pharmaceuticals Recent Developments/Updates
Table 160. Teva Company Information
Table 161. Teva Description and Business Overview
Table 162. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. Teva Oral Medications for Multiple Sclerosis Product
Table 164. Teva Recent Developments/Updates
Table 165. Sandoz Company Information
Table 166. Sandoz Description and Business Overview
Table 167. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 168. Sandoz Oral Medications for Multiple Sclerosis Product
Table 169. Sandoz Recent Developments/Updates
Table 170. Viatris Company Information
Table 171. Viatris Description and Business Overview
Table 172. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 173. Viatris Oral Medications for Multiple Sclerosis Product
Table 174. Viatris Recent Developments/Updates
Table 175. Sun Pharmaceuticals Company Information
Table 176. Sun Pharmaceuticals Description and Business Overview
Table 177. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 178. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product
Table 179. Sun Pharmaceuticals Recent Developments/Updates
Table 180. Alembic Company Information
Table 181. Alembic Description and Business Overview
Table 182. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 183. Alembic Oral Medications for Multiple Sclerosis Product
Table 184. Alembic Recent Developments/Updates
Table 185. Apotex Company Information
Table 186. Apotex Description and Business Overview
Table 187. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 188. Apotex Oral Medications for Multiple Sclerosis Product
Table 189. Apotex Recent Developments/Updates
Table 190. Key Raw Materials Lists
Table 191. Raw Materials Key Suppliers Lists
Table 192. Oral Medications for Multiple Sclerosis Distributors List
Table 193. Oral Medications for Multiple Sclerosis Customers List
Table 194. Oral Medications for Multiple Sclerosis Market Trends
Table 195. Oral Medications for Multiple Sclerosis Market Drivers
Table 196. Oral Medications for Multiple Sclerosis Market Challenges
Table 197. Oral Medications for Multiple Sclerosis Market Restraints
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
Table 201. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oral Medications for Multiple Sclerosis
Figure 2. Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oral Medications for Multiple Sclerosis Market Share by Type: 2023 & 2030
Figure 4. Dimethyl Fumarate Product Picture
Figure 5. Fingolimod Product Picture
Figure 6. Teriflunomide Product Picture
Figure 7. Diroximel Fumarate Product Picture
Figure 8. Monomethyl Fumarate Product Picture
Figure 9. Siponimod Product Picture
Figure 10. Ozanimod Product Picture
Figure 11. Ponesimod Product Picture
Figure 12. Cladribine Product Picture
Figure 13. Global Oral Medications for Multiple Sclerosis Market Value by Application (2024-2030) & (US$ Million)
Figure 14. Global Oral Medications for Multiple Sclerosis Market Share by Application: 2023 & 2030
Figure 15. Hospital and Clinic
Figure 16. Retail Pharmacies
Figure 17. Other
Figure 18. Global Oral Medications for Multiple Sclerosis Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Oral Medications for Multiple Sclerosis Market Size (2019-2030) & (US$ Million)
Figure 20. Global Oral Medications for Multiple Sclerosis Sales (2019-2030) & (K Units)
Figure 21. Global Oral Medications for Multiple Sclerosis Average Price (US$/Unit) & (2019-2030)
Figure 22. Oral Medications for Multiple Sclerosis Report Years Considered
Figure 23. Oral Medications for Multiple Sclerosis Sales Share by Manufacturers in 2023
Figure 24. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers in 2023
Figure 25. Global 5 and 10 Largest Oral Medications for Multiple Sclerosis Players: Market Share by Revenue in Oral Medications for Multiple Sclerosis in 2023
Figure 26. Oral Medications for Multiple Sclerosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 27. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 28. North America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 29. North America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2030)
Figure 30. United States Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Canada Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Europe Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 33. Europe Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2030)
Figure 34. Germany Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. France Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. U.K. Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Italy Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Russia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Asia Pacific Oral Medications for Multiple Sclerosis Sales Market Share by Region (2019-2030)
Figure 40. Asia Pacific Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2019-2030)
Figure 41. China Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Japan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. South Korea Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. India Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Australia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. China Taiwan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 49. Mexico Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Brazil Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Argentina Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Colombia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 54. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Oral Medications for Multiple Sclerosis by Type (2019-2030)
Figure 59. Global Revenue Market Share of Oral Medications for Multiple Sclerosis by Type (2019-2030)
Figure 60. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Oral Medications for Multiple Sclerosis by Application (2019-2030)
Figure 62. Global Revenue Market Share of Oral Medications for Multiple Sclerosis by Application (2019-2030)
Figure 63. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2019-2030)
Figure 64. Oral Medications for Multiple Sclerosis Value Chain
Figure 65. Oral Medications for Multiple Sclerosis Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Oral Medications for Multiple Sclerosis Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Oral Medications for Multiple Sclerosis Market Competitive Situation by Manufacturers in 2023
Table 4. Global Oral Medications for Multiple Sclerosis Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Oral Medications for Multiple Sclerosis Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Oral Medications for Multiple Sclerosis, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Product Type & Application
Table 12. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Medications for Multiple Sclerosis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Medications for Multiple Sclerosis as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Oral Medications for Multiple Sclerosis Sales by Region (2019-2024) & (K Units)
Table 18. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2019-2024)
Table 19. Global Oral Medications for Multiple Sclerosis Sales by Region (2025-2030) & (K Units)
Table 20. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2025-2030)
Table 21. Global Oral Medications for Multiple Sclerosis Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2019-2024)
Table 23. Global Oral Medications for Multiple Sclerosis Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2025-2030)
Table 25. North America Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 27. North America Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 28. North America Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Oral Medications for Multiple Sclerosis Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 32. Europe Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 33. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2019-2024) & (K Units)
Table 47. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2025-2030) & (K Units)
Table 48. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Type (2019-2024)
Table 51. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Type (2025-2030)
Table 52. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2019-2024)
Table 53. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2025-2030)
Table 54. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2019-2024)
Table 57. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2025-2030)
Table 58. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2019-2024)
Table 59. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2025-2030)
Table 60. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Application (2019-2024)
Table 61. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Application (2025-2030)
Table 62. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2019-2024)
Table 63. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2025-2030)
Table 64. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2019-2024)
Table 67. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2025-2030)
Table 68. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2019-2024)
Table 69. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2025-2030)
Table 70. Janssen Company Information
Table 71. Janssen Description and Business Overview
Table 72. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Janssen Oral Medications for Multiple Sclerosis Product
Table 74. Janssen Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Novartis Oral Medications for Multiple Sclerosis Product
Table 79. Novartis Recent Developments/Updates
Table 80. Sanofi Company Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Sanofi Oral Medications for Multiple Sclerosis Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Biogen Company Information
Table 86. Biogen Description and Business Overview
Table 87. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Biogen Oral Medications for Multiple Sclerosis Product
Table 89. Biogen Recent Developments/Updates
Table 90. Banner Life Sciences Company Information
Table 91. Banner Life Sciences Description and Business Overview
Table 92. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Banner Life Sciences Oral Medications for Multiple Sclerosis Product
Table 94. Banner Life Sciences Recent Developments/Updates
Table 95. Bristol Myers Squibb Company Information
Table 96. Bristol Myers Squibb Description and Business Overview
Table 97. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product
Table 99. Bristol Myers Squibb Recent Developments/Updates
Table 100. Merck Company Information
Table 101. Merck Description and Business Overview
Table 102. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Merck Oral Medications for Multiple Sclerosis Product
Table 104. Merck Recent Developments/Updates
Table 105. Qilu Pharmaceutical Company Information
Table 106. Qilu Pharmaceutical Description and Business Overview
Table 107. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 109. Qilu Pharmaceutical Recent Developments/Updates
Table 110. Sichuan Omnis Pharmaceutical Company Information
Table 111. Sichuan Omnis Pharmaceutical Description and Business Overview
Table 112. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 114. Sichuan Omnis Pharmaceutical Recent Developments/Updates
Table 115. HEC Pharm Company Information
Table 116. HEC Pharm Description and Business Overview
Table 117. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. HEC Pharm Oral Medications for Multiple Sclerosis Product
Table 119. HEC Pharm Recent Developments/Updates
Table 120. Cisen Pharmaceutical Company Information
Table 121. Cisen Pharmaceutical Description and Business Overview
Table 122. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 124. Cisen Pharmaceutical Recent Developments/Updates
Table 125. Nanjing Healthnice Pharmaceutical Company Information
Table 126. Nanjing Healthnice Pharmaceutical Description and Business Overview
Table 127. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 129. Nanjing Healthnice Pharmaceutical Recent Developments/Updates
Table 130. CGeneTech (Suzhou, China) Company Information
Table 131. CGeneTech (Suzhou, China) Description and Business Overview
Table 132. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product
Table 134. CGeneTech (Suzhou, China) Recent Developments/Updates
Table 135. Mylan Company Information
Table 136. Mylan Description and Business Overview
Table 137. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Mylan Oral Medications for Multiple Sclerosis Product
Table 139. Mylan Recent Developments/Updates
Table 140. Zydus Company Information
Table 141. Zydus Description and Business Overview
Table 142. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Zydus Oral Medications for Multiple Sclerosis Product
Table 144. Zydus Recent Developments/Updates
Table 145. Accord Healthcare Company Information
Table 146. Accord Healthcare Description and Business Overview
Table 147. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Accord Healthcare Oral Medications for Multiple Sclerosis Product
Table 149. Accord Healthcare Recent Developments/Updates
Table 150. Dr. Reddy's Laboratories Company Information
Table 151. Dr. Reddy's Laboratories Description and Business Overview
Table 152. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product
Table 154. Dr. Reddy's Laboratories Recent Developments/Updates
Table 155. Glenmark Pharmaceuticals Company Information
Table 156. Glenmark Pharmaceuticals Description and Business Overview
Table 157. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product
Table 159. Glenmark Pharmaceuticals Recent Developments/Updates
Table 160. Teva Company Information
Table 161. Teva Description and Business Overview
Table 162. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. Teva Oral Medications for Multiple Sclerosis Product
Table 164. Teva Recent Developments/Updates
Table 165. Sandoz Company Information
Table 166. Sandoz Description and Business Overview
Table 167. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 168. Sandoz Oral Medications for Multiple Sclerosis Product
Table 169. Sandoz Recent Developments/Updates
Table 170. Viatris Company Information
Table 171. Viatris Description and Business Overview
Table 172. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 173. Viatris Oral Medications for Multiple Sclerosis Product
Table 174. Viatris Recent Developments/Updates
Table 175. Sun Pharmaceuticals Company Information
Table 176. Sun Pharmaceuticals Description and Business Overview
Table 177. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 178. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product
Table 179. Sun Pharmaceuticals Recent Developments/Updates
Table 180. Alembic Company Information
Table 181. Alembic Description and Business Overview
Table 182. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 183. Alembic Oral Medications for Multiple Sclerosis Product
Table 184. Alembic Recent Developments/Updates
Table 185. Apotex Company Information
Table 186. Apotex Description and Business Overview
Table 187. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 188. Apotex Oral Medications for Multiple Sclerosis Product
Table 189. Apotex Recent Developments/Updates
Table 190. Key Raw Materials Lists
Table 191. Raw Materials Key Suppliers Lists
Table 192. Oral Medications for Multiple Sclerosis Distributors List
Table 193. Oral Medications for Multiple Sclerosis Customers List
Table 194. Oral Medications for Multiple Sclerosis Market Trends
Table 195. Oral Medications for Multiple Sclerosis Market Drivers
Table 196. Oral Medications for Multiple Sclerosis Market Challenges
Table 197. Oral Medications for Multiple Sclerosis Market Restraints
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
Table 201. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oral Medications for Multiple Sclerosis
Figure 2. Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oral Medications for Multiple Sclerosis Market Share by Type: 2023 & 2030
Figure 4. Dimethyl Fumarate Product Picture
Figure 5. Fingolimod Product Picture
Figure 6. Teriflunomide Product Picture
Figure 7. Diroximel Fumarate Product Picture
Figure 8. Monomethyl Fumarate Product Picture
Figure 9. Siponimod Product Picture
Figure 10. Ozanimod Product Picture
Figure 11. Ponesimod Product Picture
Figure 12. Cladribine Product Picture
Figure 13. Global Oral Medications for Multiple Sclerosis Market Value by Application (2024-2030) & (US$ Million)
Figure 14. Global Oral Medications for Multiple Sclerosis Market Share by Application: 2023 & 2030
Figure 15. Hospital and Clinic
Figure 16. Retail Pharmacies
Figure 17. Other
Figure 18. Global Oral Medications for Multiple Sclerosis Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Oral Medications for Multiple Sclerosis Market Size (2019-2030) & (US$ Million)
Figure 20. Global Oral Medications for Multiple Sclerosis Sales (2019-2030) & (K Units)
Figure 21. Global Oral Medications for Multiple Sclerosis Average Price (US$/Unit) & (2019-2030)
Figure 22. Oral Medications for Multiple Sclerosis Report Years Considered
Figure 23. Oral Medications for Multiple Sclerosis Sales Share by Manufacturers in 2023
Figure 24. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers in 2023
Figure 25. Global 5 and 10 Largest Oral Medications for Multiple Sclerosis Players: Market Share by Revenue in Oral Medications for Multiple Sclerosis in 2023
Figure 26. Oral Medications for Multiple Sclerosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 27. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 28. North America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 29. North America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2030)
Figure 30. United States Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Canada Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Europe Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 33. Europe Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2030)
Figure 34. Germany Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. France Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. U.K. Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Italy Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Russia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Asia Pacific Oral Medications for Multiple Sclerosis Sales Market Share by Region (2019-2030)
Figure 40. Asia Pacific Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2019-2030)
Figure 41. China Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Japan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. South Korea Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. India Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Australia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. China Taiwan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 49. Mexico Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Brazil Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Argentina Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Colombia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share by Country (2019-2030)
Figure 54. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE Oral Medications for Multiple Sclerosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Oral Medications for Multiple Sclerosis by Type (2019-2030)
Figure 59. Global Revenue Market Share of Oral Medications for Multiple Sclerosis by Type (2019-2030)
Figure 60. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Oral Medications for Multiple Sclerosis by Application (2019-2030)
Figure 62. Global Revenue Market Share of Oral Medications for Multiple Sclerosis by Application (2019-2030)
Figure 63. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2019-2030)
Figure 64. Oral Medications for Multiple Sclerosis Value Chain
Figure 65. Oral Medications for Multiple Sclerosis Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232